SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 2 — Focused Visit (Follow-up) — Leonard Nimoy — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientLeonard Nimoy
Date of birth1931-03-26
IdentifiersMRN HR-ML017-SYN-TD; SSN (made up) 000-17-6604
Document date2014-03-10
AuthorCarla Benedetti, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Four-week COPD review after starting tiotropium-olodaterol. [S]

History of Present Illness

Mr. Nimoy returns four weeks after starting tiotropium-olodaterol two inhalations each morning. He feels a little less tight in the chest in the mornings and has cut his albuterol from once or twice a day to about four times a week. He still has to stop for breath after about 100 meters on level ground. The dose counter shows no missed doses. He has had no flare-up, increase in sputum, fever, or need for antibiotics or prednisone. He has no dry mouth, difficulty passing urine, palpitations, or tremor. He saw the pulmonologist this morning, and his 6-minute walk test was done in the pulmonary function laboratory. He starts pulmonary rehabilitation next week. [S]

ElementDetail
Interval changeMornings easier; still stops after about 100 meters
Reliever useAlbuterol about four times a week, down from once or twice a day
AdherenceNo missed doses by dose counter
ExacerbationsNone since intake, and none in the past 12 months
Medication toleranceNo dry mouth, urinary difficulty, palpitations, or tremor

Review of Systems

SystemResultFinding
RespiratoryPositiveBreathless on walking about 100 meters or one flight of stairs; little cough; small amount of clear morning sputum
CardiovascularNegativeNo chest pain, palpitations, orthopnea, or ankle swelling
GenitourinaryNegativeNo hesitancy or retention
PsychiatricNegativeMood steady; no panic with breathlessness

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Albuterol 90 mcg/actuation inhaler, two inhalations as needed for breathlessness (prescribed by his previous clinician; used once or twice most days before intake)Two inhalations every 4 hours as needed, with a spacerRespiratory tract route2013-09-15activeS
Tiotropium-olodaterol 2.5/2.5 mcg soft mist inhaler, two inhalations once dailyTwo inhalations once each morningRespiratory tract route2014-02-10activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2014-03-10Body height185cmS
2014-03-10Body weight80.2kgS
2014-03-10Body mass index (BMI) [Ratio]23.4kg/m2S
2014-03-10Systolic blood pressure128mm[Hg]S
2014-03-10Diastolic blood pressure76mm[Hg]S
2014-03-10Heart rate82/minS
2014-03-10Respiratory rate18/minS
2014-03-10Body temperature36.6CelS
2014-03-10Oxygen saturation in Arterial blood by Pulse oximetry93%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2014-03-10Six minute walk test270mPredicted about 480 m for his age, sex, height, and weight; lower limit about 380 mLowS

Physical Exam

Vital signs recorded on 2014-03-10; see the Vital Signs section. [S]

SystemFinding
GeneralSpeaks in full sentences; no use of accessory muscles at rest
LungsReduced breath sounds throughout with prolonged expiration; no wheeze or crackles
CardiovascularRegular rhythm at 82 per minute; no edema
Inhaler techniqueCorrect with his soft mist inhaler: slow, deep breath with the dose and a ten-second breath hold

Problems

ProblemClinical statusVerificationCodeProvenance
Chronic obstructive pulmonary disease, GOLD 3 (severe airflow limitation), group B, confirmed on spirometry; synthetic modern classification linked to his publicly disclosed COPDactiveconfirmed J44.9S — Synthetic modern spirometric classification; the COPD diagnosis itself is D from his own public disclosure.
Former smoker, quit about 30 years ago through a cessation programactiveconfirmed Z87.891S — Synthetic modern entry linked to his public account of quitting smoking.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
SurveyCOPD Assessment Test (CAT)Every visitCompleted today19, down from 22 at intake; a change of 2 or more is meaningful
SurveymMRC dyspnea gradeEvery visitCompleted todayGrade 3, unchanged
SurveyExacerbation history and GOLD groupEvery visitCompleted todayNo moderate or severe exacerbation in the past 12 months; group B
ExaminationPulse oximetryEvery visitCompleted today93 percent at rest on room air
Self-managementSmoking status and cessation supportEvery visitCompleted todayFormer smoker; no tobacco for about 30 years
ExaminationBMI and nutritional statusEvery visitCompleted todayBMI 23.4; weight stable
ExaminationInhaler technique and adherenceEvery visitCompleted todayCorrect technique; no missed doses
Examination6-minute walk testAt pulmonary rehabilitation entry and exit, and for oxygen assessmentCompleted today270 m at rehabilitation entry; lowest saturation 89 percent
ExaminationLong-term oxygen assessmentAs indicated: resting saturation 88 percent or less, confirmed twice at least three weeks apartCompleted todayNot met: 93 percent at rest and 89 percent at the lowest on exertion; no oxygen prescribed
LaboratoryArterial blood gasAs indicated: resting saturation 92 percent or less, oxygen qualification, or suspected hypercapniaNot indicatedResting saturation 93 percent; no sign of hypercapnia
ExaminationSpirometryAt diagnosis, then at least yearly and with significant clinical changeUp to dateDiagnostic spirometry at intake: post-bronchodilator FEV1/FVC 0.43, FEV1 46 percent predicted; next in one year
LaboratoryAlpha-1 antitrypsinOnce, at diagnosisUp to date138 mg/dL at intake, normal; not repeated
LaboratoryBlood eosinophil countAt baseline and when an inhaled corticosteroid is consideredUp to date0.18 x10³/µL at intake; no inhaled corticosteroid while there are no exacerbations
ExaminationECG and cardiovascular risk assessmentAt baseline and after exacerbationsUp to dateIntake ECG in sinus rhythm with no abnormality; blood pressure normal
SurveyMood and comorbidity screeningAt diagnosis and yearlyUp to datePHQ-9 3 and GAD-2 1 at intake; no reflux, sleep, or nutrition concern
ReferralPulmonology consultationWhen the diagnosis, severity, or treatment needs specialist reviewCompleted todaySeen today; GOLD 3, group B confirmed; current inhaler continued
ReferralPulmonary rehabilitationStable mMRC 2 or more or CAT 10 or more; within three weeks of any hospital stay for an exacerbationReferredProgram begins next week
Medication safetyVaccination statusReviewed yearlyDeferredHigh-dose influenza vaccine this past autumn, zoster series complete, Tdap within ten years. PCV20 was planned today but the clinic was out of stock, so it was not given; to be given at the next visit
ImagingLow-dose chest CTAs indicated, or yearly lung cancer screening if eligibleNot indicatedNo suspected complication; not eligible for screening, because he quit more than 15 years ago

Goal progress:

Guideline basis: Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, 2025 report (2025); CMID: Clinical Monitoring Intelligence Database, chronic obstructive pulmonary disease monograph (2026); Pulmonary Rehabilitation for Adults with Chronic Respiratory Disease: An Official American Thoracic Society Clinical Practice Guideline (2023); Home Oxygen Therapy for Adults with Chronic Lung Disease: An Official American Thoracic Society Clinical Practice Guideline (2020)

Follow-up: Pulmonary rehabilitation from next week. COPD review in two months, after rehabilitation. Next scheduled visit 2014-05-12: three-month COPD review after pulmonary rehabilitation. [S]